316.14
-4.10 (-1.28%)
| Previous Close | 320.24 |
| Open | 325.12 |
| Volume | 252,273 |
| Avg. Volume (3M) | 460,851 |
| Market Cap | 8,804,762,624 |
| Price / Sales | 953.14 |
| Price / Book | 10.70 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.02% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,245.00 (HC Wainwright & Co., 293.81%) | Buy |
| Median | 505.00 (59.74%) | |
| Low | 130.00 (Wedbush, -58.88%) | Sell |
| Average | 577.88 (82.79%) | |
| Total | 6 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 327.71 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 500.00 (58.16%) | Buy | 342.71 |
| Baird | 20 Feb 2026 | 433.00 (36.96%) | Buy | 335.28 |
| Truist Securities | 20 Feb 2026 | 700.00 (121.42%) | Buy | 335.28 |
| Wedbush | 20 Feb 2026 | 130.00 (-58.88%) | Sell | 335.28 |
| Wells Fargo | 20 Feb 2026 | 305.00 (-3.52%) | Hold | 335.28 |
| 02 Feb 2026 | 282.00 (-10.80%) | Hold | 309.11 | |
| Guggenheim | 10 Feb 2026 | 800.00 (153.05%) | Buy | 320.48 |
| Needham | 04 Feb 2026 | 510.00 (61.32%) | Buy | 303.34 |
| HC Wainwright & Co. | 30 Jan 2026 | 1,245.00 (293.81%) | Buy | 314.00 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |